Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.6 - $11.2 $98,517 - $306,499
-27,366 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$8.58 - $17.65 $24,967 - $51,361
-2,910 Reduced 9.61%
27,366 $319,000
Q4 2021

Feb 09, 2022

BUY
$10.17 - $18.96 $307,906 - $574,032
30,276 New
30,276 $553,000
Q4 2020

Feb 03, 2021

SELL
$18.13 - $25.18 $595,425 - $826,961
-32,842 Closed
0 $0
Q3 2020

Nov 04, 2020

SELL
$17.83 - $29.12 $25,354 - $41,408
-1,422 Reduced 4.15%
32,842 $693,000
Q2 2020

Aug 05, 2020

SELL
$27.86 - $35.93 $127,264 - $164,128
-4,568 Reduced 11.76%
34,264 $990,000
Q1 2020

May 06, 2020

SELL
$23.65 - $40.96 $107,229 - $185,712
-4,534 Reduced 10.46%
38,832 $1.36 Million
Q4 2019

Feb 07, 2020

BUY
$13.55 - $26.15 $587,609 - $1.13 Million
43,366 New
43,366 $1.06 Million

Others Institutions Holding OYST

About Oyster Point Pharma, Inc.


  • Ticker OYST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,831,500
  • Description
  • Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...
More about OYST
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.